These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 29459028)

  • 1. Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.
    Singh SS; Jois SD
    Adv Protein Chem Struct Biol; 2018; 111():1-59. PubMed ID: 29459028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proximity ligation assay to study protein-protein interactions of proteins on two different cells.
    Sable R; Jambunathan N; Singh S; Pallerla S; Kousoulas KG; Jois S
    Biotechniques; 2018 Sep; 65(3):149-157. PubMed ID: 30227746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of protein-protein interactions using designed molecules.
    Wilson AJ
    Chem Soc Rev; 2009 Dec; 38(12):3289-300. PubMed ID: 20449049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors.
    Sable R; Jois S
    Molecules; 2015 Jun; 20(6):11569-603. PubMed ID: 26111183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of α-helix-mediated protein-protein interactions using designed molecules.
    Azzarito V; Long K; Murphy NS; Wilson AJ
    Nat Chem; 2013 Mar; 5(3):161-73. PubMed ID: 23422557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of protein-protein interactions in drug discovery.
    Andrei SA; Sijbesma E; Hann M; Davis J; O'Mahony G; Perry MWD; Karawajczyk A; Eickhoff J; Brunsveld L; Doveston RG; Milroy LG; Ottmann C
    Expert Opin Drug Discov; 2017 Sep; 12(9):925-940. PubMed ID: 28695752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmark Study Based on 2P2I
    Wang Z; Kang Y; Li D; Sun H; Dong X; Yao X; Xu L; Chang S; Li Y; Hou T
    J Phys Chem B; 2018 Mar; 122(9):2544-2555. PubMed ID: 29420886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using peptides to study protein-protein interactions.
    Benyamini H; Friedler A
    Future Med Chem; 2010 Jun; 2(6):989-1003. PubMed ID: 21426115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPI inhibitor and stabilizer development in human diseases.
    Bosch J
    Drug Discov Today Technol; 2017 Jun; 24():3-9. PubMed ID: 29233297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer.
    Kanakaveti V; Anoosha P; Sakthivel R; Rayala SK; Gromiha MM
    Curr Top Med Chem; 2019; 19(6):457-466. PubMed ID: 30836917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hot spot-based design of small-molecule inhibitors for protein-protein interactions.
    Guo W; Wisniewski JA; Ji H
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2546-54. PubMed ID: 24751445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.
    Sheng C; Dong G; Miao Z; Zhang W; Wang W
    Chem Soc Rev; 2015 Nov; 44(22):8238-59. PubMed ID: 26248294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
    Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
    Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein-protein interaction inhibitors: advances in anticancer drug design.
    Ferreira LG; Oliva G; Andricopulo AD
    Expert Opin Drug Discov; 2016 Oct; 11(10):957-68. PubMed ID: 27554357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting protein-protein interactions as an emerging paradigm for drug discovery.
    Gerrard JA; Hutton CA; Perugini MA
    Mini Rev Med Chem; 2007 Feb; 7(2):151-7. PubMed ID: 17305589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format.
    Hashimoto J; Watanabe T; Seki T; Karasawa S; Izumikawa M; Seki T; Iemura S; Natsume T; Nomura N; Goshima N; Miyawaki A; Takagi M; Shin-Ya K
    J Biomol Screen; 2009 Sep; 14(8):970-9. PubMed ID: 19641222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances.
    Kuenemann MA; Sperandio O; Labbé CM; Lagorce D; Miteva MA; Villoutreix BO
    Prog Biophys Mol Biol; 2015 Oct; 119(1):20-32. PubMed ID: 25748546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Split-enzyme immunoassay to monitor EGFR-HER2 heterodimerization on cell surfaces.
    Kim SJ; Dixon AS; Owen SC
    Acta Biomater; 2021 Nov; 135():225-233. PubMed ID: 34496282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
    Buchwald P
    IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening-based approaches to identify small molecules that inhibit protein-protein interactions.
    Choi S; Choi KY
    Expert Opin Drug Discov; 2017 Mar; 12(3):293-303. PubMed ID: 28067063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.